Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective January 13, 2025 AUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to Rein Therapeutics, Inc. The new

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data from Cohort 2 of the Phase 1b clinical trial confirms results from Cohort 1, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set Planning is underway for a Phase 2 clinical trial AUSTIN, Texas, Nov. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significan

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2

4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

4 - AILERON THERAPEUTICS INC (0001420565) (Issuer)

4 - AILERON THERAPEUTICS INC (0001420565) (Issuer)

4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

4 - Aileron Therapeutics, Inc. (0001420565) (Issuer)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

8-K - Aileron Therapeutics, Inc. (0001420565) (Filer)

10-Q - Aileron Therapeutics, Inc. (0001420565) (Filer)

AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S.

Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of 2024 AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron", the "Company", "we", "our" or "us") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended Decemb

Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join th

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024 Company to host conference call on Wednesday, May 1st at 9:00 am ET WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint  Evaluating cycles 1-6, the imbalance increases further (79% of cycles on ALRN-6924 versus 57% on placebo) Interim finding on the trial's composite primary endpoint, which was the proportion of treatment cycles free of Grade ≥3 neutropenia, anemia, thrombocytopenia, blood transfusions, use of growth factors, dose reductions/delays in the first 4 cycles, demonstrated 56% of cycles on ALRN-6924 ve

SC 13D/A - Aileron Therapeutics, Inc. (0001420565) (Subject)

SC 13G - AILERON THERAPEUTICS INC (0001420565) (Subject)

SC 13G/A - AILERON THERAPEUTICS INC (0001420565) (Subject)